

WJG 20<sup>th</sup> Anniversary Special Issues (12): Nonalcoholic fatty liver disease**Alimentary regimen in non-alcoholic fatty liver disease:  
Mediterranean diet**

Ludovico Abenavoli, Natasa Milic, Valentina Peta, Francesco Alfieri, Antonino De Lorenzo, Stefano Bellentani

Ludovico Abenavoli, Valentina Peta, Department of Health Sciences, University Magna Graecia, Campus Germaneto, 88100 Catanzaro, Italy

Natasa Milic, Department of Pharmacy, University of Novi Sad, 21000 Novi Sad, Serbia

Francesco Alfieri, University MEIER, 20124 Baranzate (MI), Italy

Antonino De Lorenzo, Division of Clinical Nutrition and Nutrigenomic, Department of Biomedicine and Prevention, University of Tor Vergata, 00133 Rome, Italy

Stefano Bellentani, Azienda USL di Modena, Consultant for Primary Care Gastroenterology, "Ramazzini" Hospital, 42100 Carpi (Modena), Italy

**Author contributions:** Abenavoli L designed the paper, performed research of literature data and wrote the paper; Milic N and Alfieri F performed research of literature data and critically revised the paper; Peta V help to wrote the paper; De Lorenzo A and Bellentani S analysed data and drafted the article.

**Correspondence to:** Ludovico Abenavoli, MD, PhD, Department of Health Sciences, University Magna Graecia, Campus Germaneto, Viale Europa, 88100 Catanzaro, Italy. [l.abenavoli@unicz.it](mailto:l.abenavoli@unicz.it)

Telephone: +39-961-3694387 Fax: +39-961-754220

Received: March 18, 2014 Revised: July 20, 2014

Accepted: September 12, 2014

Published online: December 7, 2014

**Abstract**

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide. The mechanisms of the underlying disease development and progression are awaiting clarification. Insulin resistance and obesity-related inflammation status, among other possible genetic, dietary, and lifestyle factors, are thought to play the key role. There is no consensus concerning the pharmacological treatment. However, the dietary nutritional management to achieve weight loss is an essential component of any treatment strategy. On the basis of its components, the literature reports on the effectiveness of the Mediterranean diet in reducing cardio-

vascular risk and in preventing major chronic diseases, including obesity and diabetes. New evidence supports the idea that the Mediterranean diet, associated with physical activity and cognitive behaviour therapy, may have an important role in the prevention and the treatment of NAFLD.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Insulin resistance; Nutrition; Mediterranean diet

**Core tip:** The Mediterranean diet, a dietary pattern typical of the Mediterranean area is a very healthy dietary regimen. Several studies have shown that the people with high adherence to this diet secure a longer life expectancy and a lower risk of suffering from certain chronic diseases, including cardiovascular disease, metabolic disorders and cancer. The beneficial effects of the Mediterranean diet on non-alcoholic fatty liver disease have recently been investigated.

Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. *World J Gastroenterol* 2014; 20(45): 16831-16840 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v20/i45/16831.htm> DOI: <http://dx.doi.org/10.3748/wjg.v20.i45.16831>

**INTRODUCTION**

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide<sup>[1]</sup>. NAFLD is defined as the accumulation of lipids within the hepatocytes exceeding 5% of liver weight in the absence of excessive ethanol intake (conventionally defined as an intake of ethanol

20 g/d) and without other causes of liver diseases<sup>[2]</sup>. The reported prevalence of NAFLD in the Western world is between 20%-30% in the general adult population, and in particular in the countries of Mediterranean area (*i.e.*, Italy and Greece)<sup>[3-5]</sup> and between 15%-20% in Asian countries (*i.e.*, India, China, Japan)<sup>[6-8]</sup>. The prevalence of NAFLD is 80%-90% in obese, 30%-50% in patients with diabetes and up to 90% in patients with hyperlipidemia<sup>[1]</sup>. It is estimated that 2%-3% of NAFLD present an active disease with inflammation (non-alcoholic steatohepatitis, NASH), which may progress to advanced fibrosis, liver cirrhosis and hepatocarcinoma<sup>[9,10]</sup>. The Dallas Heart Study and the Dionysos Nutrition and Liver Study reported that 30% and 25% of United States and Italian adults are affected by NAFLD respectively<sup>[4,11,12]</sup>. In these studies, 79% of the United States patients and 55% of the Italian patients with NAFLD had normal transaminase levels, showing that the liver enzymes were not surrogate markers of NAFLD. The prevalence of NAFLD/NASH continues to rise in parallel with obesity rates. As a result, NASH cirrhosis has become a common indication for liver transplantation. Currently, NASH is the third most common indication for the liver transplantation in the United States, behind hepatitis C and alcoholic liver disease, but it is estimated to become the first between 2020 and 2025<sup>[13]</sup>.

The mechanisms involved in the occurrence of fatty liver and in the progression to a more serious disease are unclear and are probably due to a metabolic profile expressed in a context of a genetic predisposition<sup>[14,15]</sup>. Insulin resistance, oxidative stress, cytokines and obesity are identified as the major risk factors involved in NAFLD/NASH pathogenesis. These factors can promote intrahepatic fat accumulation and lipotoxicity, development of an inflammatory status, oxidative stress, apoptosis and fibrogenesis that determine the progression of the disease<sup>[16]</sup>. The evaluation of the levels of serum alanine amino-transferase (ALT) and aspartate amino-transferase (AST), has been used in clinical practice as a screening test to detect NAFLD. It was reported that using the ALT cut-off value of > 40 UI/L, diagnosed steatosis with a sensitivity of 45% and specificity of 100%<sup>[17]</sup>.

Genetic and environmental factors are involved in the pathogenesis of NAFLD. Thus, nutrition is reasonably considered to be a potential environmental factor affecting the risk for this disease<sup>[18,19]</sup>. The impact of both positive energy balance and diet composition on the development of NAFLD has been explored<sup>[20-23]</sup>. Currently, lifestyle modifications, including dietary restrictions and exercise, should be recommended as the cornerstone of the NAFLD management. The general recommendations for the diet are individualized and one should aim to achieve energy deficit of 500-1000 kcal/d depending on the body mass index (BMI) of the patient. Reduced saturated fat and total fat should constitute less than 30% of the total energy input, and the intake of refined sugars should be decreased with an increase in soluble fibre intake. The recommended physical activities are 60 min/d


for at least 3 d a week and the exercise should be progressively increased to five times a week<sup>[9,10]</sup>. The degree of hepatic fat reduction is proportional to the intensity of the lifestyle intervention and generally requires a body weight loss between 5% and 10%.

The Mediterranean diet is a dietary pattern that has extensively been associated with a favourable health outcome, mainly in relation to mortality, cardiovascular disease risk factors and cancer<sup>[24,25]</sup>. In relation to the metabolic syndrome, adhering or adopting a Mediterranean dietary pattern has a beneficial effect both on the prevention and the treatment of the metabolic syndrome, as well as on individual metabolic parameters<sup>[25]</sup>.

The aim of the present review is to describe the effects and the clinical impact of the Mediterranean diet on the NAFLD patients.

## PATHOGENESIS OF NAFLD

The pathogenesis of NAFLD involves interplay of multiple complex mechanisms (Figure 1). There is a clear link between NAFLD and obesity and between NAFLD and diabetes not caused by obesity<sup>[26,27]</sup>. It has been reported that insulin resistance is the major factor involved in the pathogenesis of NAFLD. Day and James were the first to propose a direct link between NAFLD and insulin resistance and suggested the “two hits hypothesis”<sup>[14]</sup>. The first “hit” presents the insulin resistance leading to the fat accumulation resulting in steatosis. The second “hit” is an oxidative stress, determining lipid peroxidation and increasing cytokine production, that causes the inflammation and necrosis. However, this pathogenetic hypothesis has been challenged with a “multi-hits” theory, in which insulin resistance is still the key risk factor for the development of NAFLD<sup>[28]</sup>. Metabolic syndrome is considered as a pro-inflammatory status characterised by the increased plasma levels of various pro-inflammatory cytokines, such as tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6 (IL-6)<sup>[29,30]</sup>. The increased circulating levels of cytokines, plasma free fatty acid (FFA) levels and hyperglycemia are thought to contribute to the development and progression of NAFLD<sup>[16,31]</sup>. The production of IL-6 and TNF- $\alpha$  induce the activation of various signal transduction pathways, such as serine/threonine kinases, *i.e.*, protein kinase-C (PKC), c-JUN NH2-terminal kinase-1 and inhibitor of kappa B kinase as the key events in the pathway of the fat-induced hepatic insulin resistance<sup>[32]</sup>. The activation of PKC may also interfere with the ability of insulin to phosphorylate insulin receptor substrate-2<sup>[33]</sup>. Downstream effects include: nuclear factor-kappa B and activator protein-1 translocation to the nucleus resulting in an increased production of inflammatory cytokines which inhibit the insulin action<sup>[34]</sup>. Insulin resistance is a usual implication in the patients with a metabolic syndrome; fasting and post-prandial hyperglycemia are linked to hepatic steatosis. Conversely, NAFLD worsens insulin resistance that may lead on to type 2 diabetes mellitus (T2DM) in predisposed subjects<sup>[35]</sup>. Insulin



**Figure 1** Mechanisms involved in multistep pathogenesis of non-alcoholic fatty liver disease. The development of an inflammatory status and oxidative stress can induce fibrosis, necrosis and steato-hepatitis. Insulin resistance promotes the activation of cytochrome P450 2E1, that induces cellular higher levels of reactive oxygen species (ROS) and oxidative stress, determining lipid peroxidation leading to necrosis, and activation of stellate cells with liver fibrosis. The activation of Kupffer cells by nuclear factor-kappaB (NF-κB) resulting in an increased production of inflammatory cytokines such as tumour necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2) and interleukin-6 (IL-6) that cause the development of an inflammatory status, steato-hepatitis and improve the insulin resistance. MMP: Matrix metalloproteinases; TGF: Transforming growth factor; α-SMA: α-smooth muscle actin; LPS: Lipopolysaccharide; iNOS: Inducible nitric oxide synthase.


resistance is a condition in which the body becomes less sensitive to insulin, and, therefore, the greater levels of the hormone are required to exert the same metabolic effects. In the absence of the sufficient levels of additional insulin, the body triglyceride metabolism becomes deranged. There is an increased amount of FFA in the circulation which, in turn, causes the increased levels of circulating triglycerides, measurable in the patients with NAFLD and T2DM.

The increased circulating triglycerides are the consequence of the increased dietary intake of lipids and de novo synthesis by liver, the increased lipolysis due to the peripherally reduced effects of insulin, the lack of inhibition of hormone-sensitive lipase, which continues to break down very low density lipoproteins (VLDL) into FFA. The liver responds to the increase in plasma triglyceride levels by producing more VLDL, with storage of the lipids in hepatocytes, with subsequently steatosis, as a “vicious circle”<sup>[35,36]</sup>. In addition to the increased production of FFA, the increased hepatic gluconeogenesis causes worsening of hyperglycemia and insulin resistance in the NAFLD patients<sup>[37,38]</sup>. The progression to NASH is heralded by the oxidative stress that results in lipid peroxidation, release of pro-inflammatory cytokines which, then, result in the mitochondrial damage, fibrosis and inflammation. Approximately, 30% of the simple steatosis patients progress to NASH, and about 20% of these develop cirrhosis<sup>[1,16]</sup>.

## WEIGHT LOSS AND NAFLD

The NAFLD patients are inclined to a higher energy in-

take and a higher simple carbohydrate intake when compared with the healthy controls<sup>[59]</sup>. The current standard of care for treating the NAFLD patients focuses on the lifestyle interventions, especially a diet and exercise. In particular, a healthy diet has benefits beyond the weight reduction for all NAFLD patients with and without obesity. A systematic review and meta-analysis of the randomized trials by Musso *et al.*<sup>[40]</sup> suggests that weight loss is safe and both liver and cardio-metabolic disease may benefit in NAFLD: although a ≥ 5% of weight loss improves steatosis and cardio-metabolic variables, a ≥ 7% of weight loss also improves histological disease activity in NASH. The American Association for the Study of Liver Diseases guidelines recommend a weight loss of at least 3%-5% of body weight to improve steatosis and a weight loss of up to 10% may be needed to improve necro-inflammation<sup>[10]</sup>. However, only few studies have evaluated histological improvement in NAFLD based on the biopsy results. At least three studies on weight loss in the NAFLD patients have documented the histological improvements in steatosis and inflammation with biopsies, including one in children<sup>[41-43]</sup>. Subsequently, in the largest randomized controlled trial of the lifestyle intervention in NASH, the patients were randomized 2:1 to the combination of a diet, exercise, and lifestyle modification (intervention group) or a control group, with a goal of 7% to 10% of weight reduction<sup>[44]</sup>. The primary outcome measure was an improvement in the histological NAFLD activity score after 48 wk of the treatment. The subjects in the lifestyle intervention group (*n* = 21) were assigned to an energy goal, based on their starting weight (1000 to 1200 kcal/d if the baseline weight < 90



**Figure 2 Traditional Mediterranean diet pyramid.** The Mediterranean dietary plan emphasizes daily consumption of cereal, vegetables, bread, pasta, fruit, olive oil and dairy products. Eggs, sweets, fish, poultry, potatoes, pulses and nuts are recommended weekly, and red meat a few times per month and in a very small amount.

kg, or 1200 to 1500 kcal/d if the baseline weight > 90 kg) and were instructed to consume a 25% of fat diet. The participants in the control group ( $n = 10$ ) attended the group sessions providing the basic education about NASH and the principles of healthy eating and physical activity. The lifestyle intervention group had an average weight loss of 9.3% of their weight compared with only 0.2% in the control arm ( $P = 0.005$ ). Furthermore, after the treatment, the NAFLD activity score was lower in the lifestyle intervention group compared with the control group ( $P = 0.05$ ). Those who lost  $\geq 7\%$  of their body weight had significant improvements in liver steatosis ( $P < 0.001$ ), lobular inflammation ( $P = 0.03$ ) and NAFLD activity score ( $P < 0.001$ ). Other studies, using magnetic resonance spectroscopy in assessing hepatic steatosis, demonstrated that the degree of improvement in steatosis was proportional to the amount of weight loss an individual attained, if a diet with or without exercise was implemented<sup>[45,46]</sup>.

## MEDITERRANEAN DIET COMPONENTS

The Mediterranean diet is the heritage of millennia of exchanges of people, cultures and foods of all the countries around the Mediterranean Sea basin. It has been the basis of food habits during the twentieth century in all countries of the region, originally based on Mediterranean ethnological life-styles. The UNESCO report claims: “The Mediterranean diet is a set of traditional practices, knowledge and skills passed on from generation to generation, providing a sense of belonging and continuity to the concerned communities”<sup>[47]</sup>. It has been difficult to

define the Mediterranean diet because the Mediterranean region represents a large diversity of cultures and lifestyles. Nonetheless, the traditional Mediterranean diet is a pyramid characterised with the abundance of vegetable foods and cereals, such as green and yellow vegetables, salads, legumes, bread, pasta, fruits and nuts<sup>[48]</sup>. Olive oil is the main source of fat and the intake of fish, poultry, dairy products and eggs is moderate. In addition, different amounts of wine are usually consumed in moderation with meals. Animal fats used in butter, cream and lard are not included in this diet (Figure 2).

The Mediterranean diet is associated with a lowered incidence of cardiovascular diseases, metabolic disorders, Parkinson’s and Alzheimer’s diseases and several types of cancer. The protective effect is attributed, at least in part to the high concentration of antioxidants<sup>[49,50]</sup>. Vegetables are the most important sources of phenolic compounds in the Mediterranean diet, and, in particular, the flavonoids are thought to be the essential bioactive compounds that provide health benefits<sup>[51]</sup>. Several studies have reported that the traditional diets, which consist largely of vegetables, show a low incidence of chronic diseases with numerous health benefits and the improvement in life expectancy in older people<sup>[52]</sup>. Although the exact mechanisms of these protective properties are not fully understood, it is hypothesized that carotenoids, folic acid and fibres, characteristic for this diet, can play a pivotal role in the prevention of oxidative stress<sup>[53]</sup>. In addition, vegetables are also an important source of phytoosterols that reduce cholesterol serum levels and, subsequently, the cardiovascular risk<sup>[54]</sup>.

Various fruits, another important element of the

diet, provide fibres, vitamins, minerals, flavonoids and terpenes that possess protective actions against oxidative mechanisms. The omega-3 polyunsaturated fatty acids, found in fish (eicosapentaenoic and docosahexaenoic acids), regulate haemostatic factors effectively and provide the protection of several chronic diseases<sup>[55]</sup>. Olive oil contains high levels of monounsaturated fatty acids and it is a source of several phytochemicals (*i.e.*, polyphenolic compounds, squalene and  $\alpha$ -tocopherol). Some evidence suggests that olive oil, the main source of calories in the Mediterranean diet, has health benefits on the reduction of a coronary heart disease risk, the prevention of several types of cancers, the modification of the immune and inflammatory responses and the reduction of the osteoporosis risk<sup>[55,56]</sup>. The dairy products of the Mediterranean diet, such as cheese and yoghurt, are better tolerated by the lactose-intolerant subjects. In addition, lactic acid bacteria provide the probiotic benefits, including the improvement in gastrointestinal motility and of the immune tropism<sup>[57]</sup>. The constant yoghurt intake might induce favourable changes in the gut microflora and can have a positive effect on the colon cancer risk indices<sup>[58]</sup>.

Garlic, onions, herbs and spices are used as condiments in the Mediterranean diet and may increase the palatability and the nutritional value of the food. Some of them contain large quantities of flavonoids (fennel and chives) or allicin (garlic and onion), the latter may have cardiovascular benefits and can help the improvement of the cognitive functions<sup>[52,59]</sup>. The caper, containing flavonoids (kaempferol and quercetin derivatives) and hydrocinnamic acids, is used in traditional medicine for its anti-hypertensive actions and for the treatment of rheumatic conditions<sup>[60]</sup>.

Some of the health effects of the Mediterranean diet on chronic diseases have been attributed to the polyphenols in red wine<sup>[61]</sup>. Wine exerts its protective effects by changing lipoprotein profile, coagulation and fibrinolytic cascades, platelet aggregation, oxidative mechanisms and endothelial function. The endothelium regulates vascular tone *via* the balance between the vaso-relaxation (*via* nitric oxide, NO) and vaso-constriction (*via* endothelins) factors, produced by the endothelium itself in response to different stimuli<sup>[61,62]</sup>. The researchers have reported that a moderate red wine consumption determines the cardio-protective effects, stimulating the up-regulation of NO production mediated to its polyphenol components, and, in particular, by resveratrol, a stilbene polyphenol<sup>[61,63]</sup>.

Since the 1950s, Keys *et al.*<sup>[64]</sup> have studied the diets of the Mediterranean area. The people of Greece, particularly on the island of Crete, had the longest life expectancy in the world until the 1960s, followed by the people of southern Italy, Spain, and France. Subsequently, other studies among the elderly in Greece and other European countries showed that the overall Mediterranean dietary pattern was more important for longevity than the single nutrients, and it was associated with the significant improvements in health status by a marked reduction in overall mortality<sup>[25]</sup>. These data seem to be relevant for

the public health, and, in particular, for encouraging the prevention policy based on the Mediterranean-like dietary patterns for the primary prevention of the major chronic diseases.

## STUDIES ON MEDITERRANEAN DIET IN NAFLD PATIENTS

According to the recent systematic reviews and meta-analyses, adhering or adopting a Mediterranean dietary regimen presents the beneficial effect on the prevention and the resolution of the metabolic syndrome, as well as on individual metabolic parameters<sup>[65]</sup>. However, there is no consensus on which diet is the right one for the NAFLD/NASH patients, even though the Italian Association for the Study of the Liver guidelines indicate for all NAFLD patients a low carbohydrate and low saturated fat diet, avoidance of fructose-enriched soft drinks and with the increased consumption of fruits and vegetables<sup>[9]</sup>. The favourable health effects of the Mediterranean diet on the metabolic syndrome have been demonstrated by a number of studies<sup>[66-68]</sup>. In addition, it is well-known that by managing obesity, hypertriglyceridemia, diabetes mellitus and by moderating alcohol consumption liver fat accumulation may be prevented or minimized<sup>[69]</sup>.

In the last few years, the studies have been published on the effects of the Mediterranean diet on the NAFLD patients (Table 1). Shai *et al.*<sup>[70]</sup> compared the effectiveness and safety of three nutritional protocols in a 2-year randomized controlled trial: a low-fat, restricted-calorie diet; a Mediterranean, restricted-calorie diet and a low-carbohydrate, non-restricted-calorie diet in 322 obese patients (277 males). The rates of adherence to the study diets were high (95.4% at 1 year and 84.6% at 2 years). The Mediterranean-diet group consumed the largest amounts of dietary fibre and had the highest ratio of monounsaturated to saturated fat ( $P < 0.05$ ). The low-carbohydrate group consumed the smallest amount of carbohydrates and the largest amounts of fat, protein and cholesterol and had the highest percentage of the participants with detectable urinary ketones ( $P < 0.05$ ). The mean weight loss was 2.9 kg for the low-fat group, 4.4 kg for the Mediterranean-diet group, and 4.7 kg for the low-carbohydrate group ( $P < 0.001$ ). The mean weight loss was 3.3 kg, 4.6 kg, and 5.5 kg respectively in the 272 participants who completed the intervention. The relative reduction in the ratio of the total cholesterol to high-density lipoprotein cholesterol was 20% in the low-carbohydrate group, and 12% in the low-fat group ( $P = 0.01$ ). The changes in fasting plasma glucose and insulin levels were more favourable in the patients assigned to the Mediterranean diet than in those assigned to the low-fat diet ( $P < 0.001$ ) in 36 patients with diabetes. Finally, the changes in bilirubin, alkaline phosphatase, and ALT levels were similar between the diet groups. However, the transaminases levels were significantly reduced from the baseline to 24 mo in the Mediterranean diet and the low-carbohydrate groups ( $P < 0.05$ ). Subsequently,

**Table 1** Main studies on Mediterranean diet in the treatment of non-alcoholic fatty liver disease

Ref.	Patients	Nutritional protocol	Metabolic and histological changes
Shai <i>et al</i> <sup>[70]</sup>	322 obese patients (277 males)	Low-fat diet MD Low-carbohydrate diet	Weight loss (kg): 2.9 low-fat diet, 4.4 MD, 5.5 low-carbohydrate diet TC/HDL reduction (20%) in the low-carbohydrate diet; decrease in fasting plasma glucose levels and HOMA-IR in MD Changes in adiponectin, leptin, ALP, ALT similar in all diet group
Tzima <i>et al</i> <sup>[71]</sup>	1514 males 1528 females	MD	Higher MD score was associated with lower likelihood of having the metabolic syndrome In patients without or with moderate adherence to the MD an increase in the AST/ALT ratio was associated with lower likelihood of having the metabolic syndrome In patients with greater adherence to the MD AST/ALT ratio was not associated with the presence of the metabolic syndrome
Pérez-Guisado <i>et al</i> <sup>[72]</sup>	31 obese patients (22 males)	Spanish ketogenic MD	Improvement in body weight Steatosis degree Reduction in BMI, systolic blood pressure and diastolic blood pressure, total cholesterol, triacylglycerols, glucose and LDLc Increase in HDLc
Ryan <i>et al</i> <sup>[74]</sup>	12 non-diabetic patients (6 males) with NAFLD	MD control diet (low fat-high carbohydrate diet)	Weight loss with both diets Significant reduction in hepatic steatosis with MD Insulin sensitivity improved with MD
Kontogianni <i>et al</i> <sup>[75]</sup>	73 overweight NAFLD patients (50 males)	MD	MD score was negatively correlated to serum alanine aminotransferase, insulin levels, insulin resistance index and severity of steatosis MD score was positively correlated to serum adiponectin levels
Trovato <i>et al</i> <sup>[76]</sup>	90 non-alcoholic non-diabetic patients (44 males)	MD	Significant decrease of bright liver score (BLS) Adherence to MD change and body mass index changes (multiple linear regression model) independently explain the variance of decrease of fatty liver involvement

NAFLD: Non-alcoholic fatty liver disease; MD: Mediterranean diet; TC: Total-cholesterol; HOMA-IR: Homeostasis model assessment for insulin resistance; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; ALT: Alanine amino-transferase; LDLc: Low density lipoprotein-cholesterol; HDLc: High density lipoprotein-cholesterol; BMI: Body mass index.

the ATTICA study randomly enrolled 1514 adult males and 1528 females from the area of Athens to assess the adherence to the Mediterranean diet by the Mediterranean diet score<sup>[71]</sup>. The authors found that the higher score was associated with lower likelihood of having the metabolic syndrome in a multi-adjusted analysis (OR = 0.34, 95%CI: 0.16-0.73). Stratified analysis by the level of adherence to the Mediterranean diet revealed that an increase in the AST/ALT ratio was associated with lower likelihood of having the metabolic syndrome (OR = 0.33,  $P < 0.05$  and OR = 0.34,  $P < 0.09$ , respectively) only in the patients without or with moderate adherence to the Mediterranean diet. However, when those with greater adherence to the Mediterranean diet were focused, the AST/ALT ratio was not associated with the presence of the metabolic syndrome (OR = 0.51,  $P = 0.55$ ). A Spanish pilot study assessed the effects of the variant of the Mediterranean diet, called Spanish ketogenic Mediterranean diet, on the echographic liver parameters and biochemical liver functions in 14 overweight male patients with NAFLD and metabolic syndrome<sup>[72]</sup>. This diet is a protein ketogenic diet with the incorporation of high doses of virgin olive oil and omega-3 fatty acids from fish as the main source of fat, fish as the main source of protein, green vegetables and salads as the main source of carbohydrate and moderate red wine intake<sup>[73]</sup>. The regimen was administered for 3-mo. The authors reported a significant improvement in body weight ( $P < 0.001$ ), steatosis degree and all the parameters associated with the

metabolic syndrome, in particular, the body mass index, waist circumference, fasting plasma glucose, triglycerides, high-density lipoprotein-cholesterol and blood pressure. Ryan *et al*<sup>[74]</sup> examined the effects of the Mediterranean diet in terms of insulin sensitivity and steatosis degree. Twelve overweight adult non-diabetic patients (6 males) with biopsy-proved NAFLD were recruited for a randomised, cross-over intervention trial. All subjects took both the Mediterranean diet and the control diet (a low fat-high carbohydrate diet) in random order with a 6-wk wash-out period. The insulin sensitivity was determined with a 3 h hyperinsulinemic-euglycemic clamp study, and liver steatosis was assessed with localized magnetic resonance <sup>1</sup>H spectroscopy (<sup>1</sup>H-MRS). At baseline, the subjects were abdominally obese with the elevated fasting concentrations of glucose, insulin, triglycerides and transaminases levels. Insulin-sensitivity at baseline was low ( $M = 2.7 \pm 1.0$  mg/kg per minute). The mean weight loss was not different between the two diets ( $P = 0.22$ ). The significant reduction in hepatic steatosis was evident after the Mediterranean diet period, compared to the other diet ( $39\% \pm 4\%$  vs  $7\% \pm 3\%$ ), measured by <sup>1</sup>H-MRS ( $P = 0.012$ ). In addition, the study reported the improvement in the insulin sensitivity only with the Mediterranean diet ( $P = 0.03$ ). Kontogianni *et al*<sup>[75]</sup> explored the association between the adherence to the Mediterranean diet and the clinical and histological characteristics in seventy-three adult overweight NAFLD patients (50 males). The daily adherence to the diet was estimated by the Mediterranean

diet score. The liver stiffness was assessed by transient elastography in 58 patients and performed liver biopsies in 34 patients. Fifty-eight patients were matched with 58 healthy controls in terms of age, sex and body mass index. The authors showed that the diet score was negatively correlated to the transaminase levels ( $P = 0.03$ ), insulin levels ( $P = 0.001$ ), insulin resistance index ( $P = 0.005$ ) and severity of steatosis ( $P = 0.006$ ), and was positively correlated to the serum adiponectin levels ( $P = 0.04$ ). In particular, the patients with NASH presented lower adherence to the Mediterranean diet ( $29.3 \pm 3.2$  vs  $34.1 \pm 4.4$ ,  $P = 0.004$ ), compared to the group with simple fatty liver.

In a recent study Trovato *et al.*<sup>[76]</sup> reported the effect of adherence to Mediterranean diet as a predictor of changes in the fat content of the liver in overweight patients with NAFLD. The study included 90 non-alcoholic non-diabetic patients with evidence of fatty liver by ultrasound (F 46, M 44), aged  $50.13 \pm 13.68$  years and BMI  $31.01 \pm 5.18$  kg/m<sup>2</sup>. After only 6 mo of intervention a significant decrease of bright liver score was observed; by a multiple linear regression model adherence to Mediterranean Diet change ( $P = 0.015$ ) and body mass index changes ( $P < 0.0001$ ) independently explain the variance of decrease of fatty liver involvement ( $r^2 = 0.519$ ,  $P < 0.0001$ ). This data suggested that adherence to Mediterranean diet is a significant predictor of changes in the fat content of the liver in patients with NAFLD.

Finally, recently it has been suggested that lower body iron stores induced by dietary components of Mediterranean diet could be involved in the beneficial action of this dietary pattern in NAFLD. Mounting evidence suggests a link between serum ferritin, insulin resistance, and NAFLD. Body iron excess has frequently been found in patients with metabolic syndrome, with serum ferritin showing a linear increase with the increasing number of metabolic syndrome features<sup>[77,78]</sup>. Moreover, it has been suggested that the relation between serum ferritin and most of metabolic syndrome features might be mediated by the presence of NAFLD at population-based level<sup>[79]</sup>. Excessive hepatic iron accumulation in NAFLD can be one of the potential cofactors involved in the enhanced oxidative stress, which triggers liver cell necrosis and activation of hepatic stellate cells, both leading to fibrosis<sup>[80]</sup>. On the other hand, it has been proposed that the balance between the average bioavailability of dietary iron and the overall effects of inhibitors and enhancers of iron absorption may lead to lower iron stores in people consuming a Mediterranean dietary pattern<sup>[81]</sup>. In fact, it has been reported that elderly men from Crete, in the Mediterranean south of Europe had consistently lower levels of indicators of oxidative stress and iron status than elderly men from Zutphen in the north of Europe. In particular, serum ferritin, a good marker of the iron stored in the body, were 2-fold lower in men from Crete than in men from Zutphen ( $69.8$  and  $134.2$  lg/L, respectively)<sup>[82]</sup>.

## CONCLUSION

NAFLD is the most common cause of chronic liver

disease in the developed world and the progression to simple steatosis, to steato-hepatitis and, finally, to cirrhosis represents an emerging problem of the public health. Unfortunately, a “golden standard” drug therapy for NAFLD is not currently available and the management must focus on the treatment of metabolic syndrome, and, therefore, NAFLD is often considered as an individual entity in the clinical practice. The influence of the dietary nutrients in the pathogenesis of NAFLD has been reported. The cornerstone in the management of NAFLD implies a dietary modification to decrease the body weight and to increase the physical exercise in order to reduce insulin resistance and to normalize the transaminases levels. These “easy” concepts seem to be clinically relevant in terms of cost/effectiveness, in particular, to reduce the risk of pre-mature death in general population. A diet regimen rich in monounsaturated fatty acids and omega-3, fruit, vegetables, fibre and reduced intake of saturated fats, simple carbohydrates, sweetened drinks and moderate alcohol intake should be recommended to the NAFLD patients. On the basis of its components, it is well known that the Mediterranean diet presents health benefits and can prevent obesity, diabetes and cardiovascular conditions. It is a highly palatable and favourable diet and may lead to a higher adherence among dieters in the long term.

Considering the data currently available in literature, the prescription of the Mediterranean diet by the physicians and nutritionists for the NAFLD patients may present an appropriate therapeutic option associated with lifestyle changes. It can play the primary role in the prevention and the treatment of several chronic diseases, including the spectrum of NAFLD. The well-designed dietary intervention trials are needed to define the exact dietary guidelines for NAFLD and to explain the role of the Mediterranean dietetic pattern, as the indispensable reference diet.

## REFERENCES

- 1 **Bellentani S**, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]
- 2 **Nascimbeni F**, Pais R, Bellentani S, Day CP, Ratziv V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. *J Hepatol* 2013; **59**: 859-871 [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044]
- 3 **Bellentani S**, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med* 2000; **132**: 112-117 [PMID: 10644271 DOI: 10.7326/0003-4819-132-2-200001180-00029]
- 4 **Bedogni G**, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; **42**: 44-52 [PMID: 15895401 DOI: 10.1002/hep.20734]
- 5 **Margariti E**, Deutsch M, Manolakopoulos S, Papatheodoridis GV. Non-alcoholic fatty liver disease may develop in individuals with normal body mass index. *Ann Gastroenterol* 2012; **25**: 45-51 [PMID: 24713801]
- 6 **Kawai N**, Tsugaya M, Sakagami H, Sasaki S, Kohri K. [A study of the indication for conservative surgery in adult hy-

- dronephrosis based on presurgery post-contrast computed tomography (CT) finding]. *Nihon Hinyokika Gakkai Zasshi* 1997; **88**: 997-1004 [PMID: 9465599]
- 7 **Fan JG**, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. *J Hepatol* 2009; **50**: 204-210 [PMID: 19014878 DOI: 10.1016/j.jhep.2008.10.010]
  - 8 **Amarapurkar DN**, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? *J Gastroenterol Hepatol* 2007; **22**: 788-793 [PMID: 17565631 DOI: 10.1111/j.1440-1746.2007.05042.x]
  - 9 **Loria P**, Adinolfi LE, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. *Dig Liver Dis* 2010; **42**: 272-282 [PMID: 20171943 DOI: 10.1016/j.dld.2010.01.021]
  - 10 **Chalasan N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012; **142**: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001]
  - 11 **Browning JD**. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. *Hepatology* 2006; **44**: 466-471 [PMID: 16871575 DOI: 10.1002/hep.21248]
  - 12 **Bedogni G**, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: the Dionysos study. *Hepatology* 2007; **46**: 1387-1391 [PMID: 17685472 DOI: 10.1002/hep.21827]
  - 13 **Milić S**, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. *Dig Dis* 2012; **30**: 158-162 [PMID: 22722431 DOI: 10.1159/000336669]
  - 14 **Day CP**, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998; **114**: 842-845 [PMID: 9547102]
  - 15 **Abenavoli L**, Bellentani S. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality? *Expert Rev Gastroenterol Hepatol* 2013; **7**: 677-679 [PMID: 24134155 DOI: 10.1586/17474124.2013.842893]
  - 16 **Petta S**, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. *Dig Liver Dis* 2009; **41**: 615-625 [PMID: 19223251 DOI: 10.1016/j.dld.2009.01.004]
  - 17 **Clark JM**, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. *Am J Gastroenterol* 2003; **98**: 960-967 [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x]
  - 18 **Colak Y**, Tuncer I, Senates E, Ozturk O, Doganay L, Yilmaz Y. Nonalcoholic fatty liver disease: a nutritional approach. *Metab Syndr Relat Disord* 2012; **10**: 161-166 [PMID: 22394108]
  - 19 **Abenavoli L**, Milic N. Dietary intervention in non-alcoholic fatty liver disease. *J Acad Nutr Diet* 2013; **113**: 211 [PMID: 23351623 DOI: 10.1016/j.jand.2012.11.019]
  - 20 **Solga S**, Alkhouraishe AR, Clark JM, Torbenson M, Greenwald A, Diehl AM, Magnuson T. Dietary composition and nonalcoholic fatty liver disease. *Dig Dis Sci* 2004; **49**: 1578-1583 [PMID: 15573908]
  - 21 **Ibrahim A**, Natrajan S, Ghafoorunissa R. Dietary trans-fatty acids alter adipocyte plasma membrane fatty acid composition and insulin sensitivity in rats. *Metabolism* 2005; **54**: 240-246 [PMID: 15789505]
  - 22 **Zivkovic AM**, German JB, Sanyal AJ. Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. *Am J Clin Nutr* 2007; **86**: 285-300 [PMID: 17684197]
  - 23 **Vos MB**, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. *Medscape J Med* 2008; **10**: 160 [PMID: 18769702]
  - 24 **De Lorenzo A**, Noce A, Bigioni M, Calabrese V, Della Rocca DG, Di Daniele N, Tozzo C, Di Renzo L. The effects of Italian Mediterranean organic diet (IMOD) on health status. *Curr Pharm Des* 2010; **16**: 814-824 [PMID: 20388092 DOI: 10.2174/138161210790883561]
  - 25 **Sofi F**, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr* 2010; **92**: 1189-1196 [PMID: 20810976 DOI: 10.3945/ajcn.2010.29673]
  - 26 **Gaggini M**, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. *Nutrients* 2013; **5**: 1548-1560 [PMID: 23666091 DOI: 10.3390/nu5051544]
  - 27 **Tarantino G**, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? *World J Gastroenterol* 2013; **19**: 3375-3384 [PMID: 23801829 DOI: 10.3748/wjg.v19.i22.3375]
  - 28 **Tilg H**, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. *Hepatology* 2010; **52**: 1836-1846 [PMID: 21038418 DOI: 10.1002/hep.24001]
  - 29 **Emanuela F**, Grazia M, Marco de R, Maria Paola L, Giorgio F, Marco B. Inflammation as a Link between Obesity and Metabolic Syndrome. *J Nutr Metab* 2012; **2012**: 476380 [PMID: 22523672 DOI: 10.1155/2012/476380]
  - 30 **Lamkanfi M**, Kanneganti TD. The inflammasome: a remote control for metabolic syndrome. *Cell Res* 2012; **22**: 1095-1098 [PMID: 22491474 DOI: 10.1038/cr.2012.55]
  - 31 **Asrih M**, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. *J Endocrinol* 2013; **218**: R25-R36 [PMID: 23833274 DOI: 10.1530/JOE-13-0201]
  - 32 **Tsochatzis EA**, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. *Mediators Inflamm* 2009; **2009**: 831670 [PMID: 19753129 DOI: 10.1155/2009/831670]
  - 33 **Samuel VT**, Liu ZX, Wang A, Beddow SA, Geisler JG, Kahn M, Zhang XM, Monia BP, Bhanot S, Shulman GI. Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease. *J Clin Invest* 2007; **117**: 739-745 [PMID: 17318260 DOI: 10.1172/JCI3040]
  - 34 **Barbarroja N**, Lopez-Pedraza C, Garrido-Sanchez L, Mayas MD, Oliva-Olivera W, Bernal-Lopez MR, El Bekay R, Tinahones FJ. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. *PLoS One* 2012; **7**: e48155 [PMID: 23110196 DOI: 10.1371/journal.pone.0048155]
  - 35 **Loria P**, Lonardo A, Anania F. Liver and diabetes. A vicious circle. *Hepatol Res* 2013; **43**: 51-64 [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x]
  - 36 **Cusi K**. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. *Gastroenterology* 2012; **142**: 711-725.e6 [PMID: 22326434 DOI: 10.1053/j.gastro.2012.02.003]
  - 37 **Kawano Y**, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J Gastroenterol* 2013; **48**: 434-441 [PMID: 23397118 DOI: 10.1007/s00535-013-0758-5]
  - 38 **Leamy AK**, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. *Prog Lipid Res* 2013; **52**: 165-174 [PMID: 23178552 DOI: 10.1016/j.plipres.2012.10.004]
  - 39 **Capristo E**, Miele L, Forgione A, Vero V, Farnetti S, Min-

- grone G, Greco AV, Gasbarrini G, Grieco A. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). *Eur Rev Med Pharmacol Sci* 2005; **9**: 265-268 [PMID: 16231587]
- 40 **Musso G**, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. *Diabetologia* 2012; **55**: 885-904 [PMID: 22278337 DOI: 10.1007/s00125-011-2446-4]
- 41 **Ueno T**, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. *J Hepatol* 1997; **27**: 103-107 [PMID: 9252081]
- 42 **Huang MA**, Greenon JK, Chao C, Anderson L, Peterman D, Jacobson J, Emick D, Lok AS, Conjeevaram HS. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. *Am J Gastroenterol* 2005; **100**: 1072-1081 [PMID: 15842581 DOI: 10.1111/j.1572-0241.2005.41334.x]
- 43 **Nobili V**, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with non-alcoholic fatty liver disease: a randomized, controlled trial. *Hepatology* 2008; **48**: 119-128 [PMID: 18537181 DOI: 10.1002/hep.22336]
- 44 **Promrat K**, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; **51**: 121-129 [PMID: 19827166 DOI: 10.1002/hep.23276]
- 45 **Petersen KF**, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005; **54**: 603-608 [PMID: 15734833 DOI: 10.2337/diabetes.54.3.603]
- 46 **Lazo M**, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010; **33**: 2156-2163 [PMID: 20664019 DOI: 10.2337/dc10-0856]
- 47 UNESCO. Mediterranean diet [Internet]. 2013. Available from: URL: <http://www.unesco.org/culture/ich/RL/00884>
- 48 **Bach-Faig A**, Berry EM, Lairon D, Reguant J, Trichopoulos A, Dernini S, Medina FX, Battino M, Belahsen R, Miranda G, Serra-Majem L. Mediterranean diet pyramid today. Science and cultural updates. *Public Health Nutr* 2011; **14**: 2274-2284 [PMID: 22166184 DOI: 10.1017/S1368980011002515]
- 49 **Bonaccio M**, Iacoviello L, de Gaetano G. The Mediterranean diet: the reasons for a success. *Thromb Res* 2012; **129**: 401-404 [PMID: 22100317 DOI: 10.1016/j.thromres.2011.10.018]
- 50 **Giacosa A**, Barale R, Bavaresco L, Gatenby P, Gerbi V, Janssens J, Johnston B, Kas K, La Vecchia C, Mainguet P, Morazzoni P, Negri E, Pelucchi C, Pezzotti M, Rondanelli M. Cancer prevention in Europe: the Mediterranean diet as a protective choice. *Eur J Cancer Prev* 2013; **22**: 90-95 [PMID: 22644232 DOI: 10.1097/CEJ.0b013e328354d2d7]
- 51 **Rubió L**, Motilva MJ, Romero MP. Recent advances in biologically active compounds in herbs and spices: a review of the most effective antioxidant and anti-inflammatory active principles. *Crit Rev Food Sci Nutr* 2013; **53**: 943-953 [PMID: 23768186 DOI: 10.1080/10408398.2011.574802]
- 52 **Tyrvolas S**, Panagiotakos DB. The role of Mediterranean type of diet on the development of cancer and cardiovascular disease, in the elderly: a systematic review. *Maturitas* 2010; **65**: 122-130 [PMID: 19656644 DOI: 10.1016/j.maturitas.2009.07.003]
- 53 **Azzini E**, Polito A, Fumagalli A, Intorre F, Venneria E, Durazzo A, Zaccaria M, Ciarapica D, Foddai MS, Mauro B, Raggiuzini A, Palomba L, Maiani G. Mediterranean Diet Effect: an Italian picture. *Nutr J* 2011; **10**: 125 [PMID: 22087545 DOI: 10.1186/1475-2891-10-125]
- 54 **Jones JL**, Comperatore M, Barona J, Calle MC, Andersen C, McIntosh M, Najm W, Lerman RH, Fernandez ML. A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome. *Metabolism* 2012; **61**: 366-372 [PMID: 21944261 DOI: 10.1016/j.metabol.2011.07.013]
- 55 **Di Minno MN**, Russolillo A, Lupoli R, Ambrosino P, Di Minno A, Tarantino G. Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. *World J Gastroenterol* 2012; **18**: 5839-5847 [PMID: 23139599 DOI: 10.3748/wjg.v18.i41.5839]
- 56 **Din JN**, Sarma J, Harding SA, Lyall K, Newby DE, Flapan AD. Effect of  $\omega$ -3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial. *BMJ Open* 2013; **3**: e003054 [PMID: 24071458 DOI: 10.1136/bmjopen-2013-003054]
- 57 **Abenavoli L**, Scarpellini E, Rouabhia S, Balsano C, Luzzza F. Probiotics in non-alcoholic fatty liver disease: which and when. *Ann Hepatol* 2013; **12**: 357-363 [PMID: 23619251]
- 58 **Chagas CE**, Rogero MM, Martini LA. Evaluating the links between intake of milk/dairy products and cancer. *Nutr Rev* 2012; **70**: 294-300 [PMID: 22537215 DOI: 10.1111/j.1753-4887.2012.00464]
- 59 **Aviello G**, Abenavoli L, Borrelli F, Capasso R, Izzo AA, Lembo F, Romano B, Capasso F. Garlic: empiricism or science? *Nat Prod Commun* 2009; **4**: 1785-1796 [PMID: 20120123]
- 60 **Conforti F**, Modesto S, Menichini F, Statti GA, Uzunov D, Solimene U, Duez P, Menichini F. Correlation between environmental factors, chemical composition, and antioxidative properties of caper species growing wild in Calabria (South Italy). *Chem Biodivers* 2011; **8**: 518-531 [PMID: 21404435 DOI: 10.1002/cbdv.201000050]
- 61 **Chiva-Blanch G**, Arranz S, Lamuela-Raventos RM, Estruch R. Effects of wine, alcohol and polyphenols on cardiovascular disease risk factors: evidences from human studies. *Alcohol Alcohol* 2013; **48**: 270-277 [PMID: 23408240 DOI: 10.1093/alcac/agt007]
- 62 **Covas MI**, Gambert P, Fitó M, de la Torre R. Wine and oxidative stress: up-to-date evidence of the effects of moderate wine consumption on oxidative damage in humans. *Atherosclerosis* 2010; **208**: 297-304 [PMID: 19660752 DOI: 10.1016/j.atherosclerosis.2009.06.031]
- 63 **Botden IP**, Oeseburg H, Durik M, Leijten FP, Van Vark-Van Der Zee LC, Musterd-Bhaggoe UM, Garredts IM, Seynhaeve AL, Langendonk JG, Sijbrands EJ, Danser AH, Roks AJ. Red wine extract protects against oxidative-stress-induced endothelial senescence. *Clin Sci (Lond)* 2012; **123**: 499-507 [PMID: 22563892 DOI: 10.1042/CS20110679]
- 64 **Keys A**, Menotti A, Karvonen MJ, Aravanis C, Blackburn H, Buzina R, Djordjevic BS, Dontas AS, Fidanza F, Keys MH, Kromhout D, Nedeljkovic S, Punsar S, Seccareccia F, Toshima H. The diet and 15-year death rate in the seven countries study. *Am J Epidemiol* 1986; **124**: 903-915 [PMID: 3776973]
- 65 **Kastorini CM**, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. *J Am Coll Cardiol* 2011; **57**: 1299-1313 [PMID: 21392646 DOI: 10.1016/j.jacc.2010.09.073]
- 66 **Panagiotakos DB**, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, Toutouzas P, Stefanadis C. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. *Am Heart J* 2004; **147**: 106-112 [PMID: 14691427 DOI: 10.1016/S0002-8703(03)00442-3]
- 67 **Tortosa A**, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nuñez-Cordoba JM, Martinez-Gonzalez MA.

- Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. *Diabetes Care* 2007; **30**: 2957-2959 [PMID: 17712023 DOI: 10.2337/dc07-1231]
- 68 **Esposito K**, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. *JAMA* 2004; **292**: 1440-1446 [PMID: 15383514 DOI: 10.1001/jama.292.12.1440]
- 69 **Fan JG**, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2013; **28** Suppl 4: 81-87 [PMID: 24251710 DOI: 10.1111/jgh.12244]
- 70 **Shai I**, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. *N Engl J Med* 2008; **359**: 229-241 [PMID: 18635428 DOI: 10.1056/NEJMoa0708681]
- 71 **Tzima N**, Pitsavos C, Panagiotakos DB, Chrysoshoou C, Polychronopoulos E, Skoumas J, Stefanadis C. Adherence to the Mediterranean diet moderates the association of aminotransferases with the prevalence of the metabolic syndrome: the ATTICA study. *Nutr Metab (Lond)* 2009; **6**: 30 [PMID: 19642977 DOI: 10.1186/1743-7075-6-30]
- 72 **Pérez-Guisado J**, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. *J Med Food* 2011; **14**: 677-680 [PMID: 21688989 DOI: 10.1089/jmf.2011.0075]
- 73 **Pérez-Guisado J**, Muñoz-Serrano A, Alonso-Moraga A. Spanish Ketogenic Mediterranean Diet: a healthy cardiovascular diet for weight loss. *Nutr J* 2008; **7**: 30 [PMID: 18950537 DOI: 10.1186/1475-2891-7-30]
- 74 **Ryan MC**, Itsiopoulos C, Thodis T, Ward G, Trost N, Hoferberth S, O'Dea K, Desmond PV, Johnson NA, Wilson AM. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. *J Hepatol* 2013; **59**: 138-143 [PMID: 23485520 DOI: 10.1016/j.jhep.2013.02.012]
- 75 **Kontogianni MD**, Tileli N, Margariti A, Georgoulis M, Deutsch M, Tiniakos D, Fragopoulou E, Zafiropoulou R, Manios Y, Papatheodoridis G. Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease. *Clin Nutr* 2014; **33**: 678-683 [PMID: 24064253 DOI: 10.1016/j.clnu.2013.08.014]
- 76 **Trovato FM**, Catalano D, Martines GF, Pace P, Trovato GM. Mediterranean diet and non-alcoholic fatty liver disease. The need of extended and comprehensive interventions. *Clin Nutr* 2014; Epub ahead of print [PMID: 24529325 DOI: 10.1016/j.clnu.2014.01.018]
- 77 **Mascitelli L**, Goldstein MR. Mediterranean diet, lower body iron stores and metabolic syndrome. *Int J Clin Pract* 2011; **65**: 1110 [PMID: 21923853 DOI: 10.1111/j.1742-1241.2011.02709.x]
- 78 **Mascitelli L**, Goldstein MR. Might some of the beneficial effects of the Mediterranean diet on non-alcoholic fatty liver disease be mediated by reduced iron stores? *J Hepatol* 2013; **59**: 639 [PMID: 23707366 DOI: 10.1016/j.jhep.2013.03.041]
- 79 **Zelber-Sagi S**, Nitzan-Kaluski D, Halpern Z, Oren R. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. *J Hepatol* 2007; **46**: 700-707 [PMID: 17150278 DOI: 10.1016/j.jhep.2006.09.018]
- 80 **George DK**, Goldwurm S, MacDonald GA, Cowley LL, Walker NL, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. *Gastroenterology* 1998; **114**: 311-318 [PMID: 9453491]
- 81 **Trombini P**, Piperno A. Ferritin, metabolic syndrome and NAFLD: elective attractions and dangerous liaisons. *J Hepatol* 2007; **46**: 549-552 [PMID: 17316880 DOI: 10.1016/j.jhep.2007.01.004]
- 82 **Buijsse B**, Feskens EJ, Moschandreas J, Jansen EH, Jacobs DR, Kafatos A, Kok FJ, Kromhout D. Oxidative stress, and iron and antioxidant status in elderly men: differences between the Mediterranean south (Crete) and northern Europe (Zutphen). *Eur J Cardiovasc Prev Rehabil* 2007; **14**: 495-500 [PMID: 17667637 DOI: 10.1097/HJR.0b013e3280111e41]

**P- Reviewer:** Chen LZ, Federico A, Inzaugarat E, Mascitelli L, Mendez-Sanchez N, Weiss R **S- Editor:** Gou SX  
**L- Editor:** A **E- Editor:** Wang CH





Published by **Baishideng Publishing Group Inc**

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgooffice@wjgnet.com](mailto:bpgooffice@wjgnet.com)

Help Desk: <http://www.wjgnet.com/esps/helpdesk.aspx>

<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045